Comparative Pharmacology
Head-to-head clinical analysis: FENTANYL 62 versus METHADOSE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FENTANYL 62 versus METHADOSE.
FENTANYL-62 vs METHADOSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fentanyl is a synthetic opioid agonist primarily acting on mu-opioid receptors in the central nervous system, leading to analgesia, sedation, and respiratory depression.
Methadone is a mu-opioid receptor agonist; it also acts as an NMDA receptor antagonist and inhibits serotonin and norepinephrine reuptake, contributing to its analgesic and detoxification effects. It has a long half-life and reduces opioid craving and withdrawal symptoms.
For analgesia: 50-100 mcg IV/IM every 1-2 hours as needed. For anesthesia: 2-50 mcg/kg IV. For PCA: 10-20 mcg IV with 5-10 min lockout. Transdermal: 12-100 mcg/h patch every 72 hours; start at 25 mcg/h in opioid-naive patients.
Oral: 20-40 mg once daily, titrated to effect; for opioid dependence, typical maintenance 80-120 mg/day. IV: 2.5-10 mg every 8-12 hours.
None Documented
None Documented
3–7 hours (terminal elimination half-life; prolonged in elderly, hepatic impairment, or with continuous infusion due to redistribution).
Terminal elimination half-life range: 8–59 hours (mean ~20–35 hours). In chronic use, half-life may increase due to accumulation. Context: The long half-life supports once-daily dosing for opioid dependence but requires careful titration to avoid accumulation.
Renal (primarily as metabolites, <10% unchanged; ~75% total metabolites in urine), fecal (~9% total metabolites).
Primarily renal (approximately 80%) as inactive metabolites, with about 20% eliminated via feces. Less than 10% excreted unchanged.
Category D/X
Category C
Opioid Agonist
Opioid Agonist